1. Coronavirus vaccine update: We may need a booster shot for COVID-19 vaccine; here’s what it means  Times of India
  2. Covid-19 vaccine tracker, July 31: Oxford, Johnson & Johnson shots prevent infection in monkeys  The Indian Express
  3. COVID-19 Vaccine: Pune Firm Gets Nod For Human Trial of Covishield, 1,600 People to Participate  India.com
  4. Newsmakers: For Sarah Gilbert and Stephane Bancel, failure isn't an option in the search for COVID-19 vaccine  Gulf News
  5. How to prevent racial and ethnic disparities with a COVID-19 vaccine | TheHill  The Hill
  6. View Full coverage on Google News
As the world inches closer to a coronavirus vaccine, it is also important to note that we may need more than one dose of the vaccine to battle against the novel contagion.As the world inches closer to a coronavirus vaccine, it is also important to note that we may need more than one dose of the vaccine to battle against the novel contagion.

Coronavirus vaccine update: We may need a booster shot for COVID-19 vaccine; here’s what it means | The Times of India

As the world inches closer to a coronavirus vaccine, it is also important to note that we may need more than one dose of the vaccine to battle against the novel contagion.As the world inches closer to a coronavirus vaccine, it is also important to note that we may need more than one dose of the vaccine to battle against the novel contagion.

Coronavirus vaccine update: We may need a booster shot for COVID-19 vaccine; here’s what it means | The Times of India

Central Drugs Standard Control Organisation (CDSCO) has recommended the Drug Controller to grant permission to Serum Institute if India to begin the final phase of human trials for Covid vaccine CovishieldCentral Drugs Standard Control Organisation (CDSCO) has recommended the Drug Controller to grant permission to Serum Institute if India to begin the final phase of human trials for Covid vaccine Covishield

India Inches Closer Towards Oxford Vaccine, Panel Recommends DCGI To Permit SII For Human Trials

SII had submitted a revised proposal on Wednesday after the expert panel had asked it to revise its protocol for the trials besides seeking some additional information

COVID-19 panel recommends DCGI to permit SII to conduct human trials of Oxford vaccine candidate - Express Pharma

Coronavirus (COVID-19) Vaccine Tracker, Moderna, Oxford Vaccine Latest News Update: The vaccine being developed by Oxford University has just begun phase-III human trials, while the one by Johnson & Johnson is carrying out phase-I and phase-II trials.Coronavirus (COVID-19) vaccine tracker update: The vaccine being developed by Oxford University has just begun phase-III human trials, while the one by Johnson & Johnson is carrying out phase-I and phase-II trials.

Coronavirus (COVID-19) Vaccine Tracker Latest Update, 31 July: Oxford, Johnson & Johnson vaccines prevent infection in monkeys

The federal government is not requiring basic demographic information to be collected during a clinical trial.The federal government is not requiring basic demographic information to be collected during a clinical trial.

How to prevent racial and ethnic disparities with a COVID-19 vaccine | TheHill

The federal government is not requiring basic demographic information to be collected during a clinical trial.The federal government is not requiring basic demographic information to be collected during a clinical trial.

How to prevent racial and ethnic disparities with a COVID-19 vaccine | TheHill

Even if an effective Covid vaccine is licensed, the manufacturing of doses for administration to world’s population will need collaboration among manufactures.Even if an effective Covid vaccine is licensed, the manufacturing of doses for administration to world’s population will need collaboration among manufactures.

Why in this race to Covid-19 vaccine the world will need more than one winner

Even if an effective Covid vaccine is licensed, the manufacturing of doses for administration to world’s population will need collaboration among manufactures.Even if an effective Covid vaccine is licensed, the manufacturing of doses for administration to world’s population will need collaboration among manufactures.

Why in this race to Covid-19 vaccine the world will need more than one winner

The COVAX scheme that aims to ensure poorer nations will have access to a Covid-19 vaccine when it arrives is already being undermined by rich Western nations ordering hundreds of millions of doses in an “us first” strategy.The COVAX scheme that aims to ensure poorer nations will have access to a Covid-19 vaccine when it arrives is already being undermined by rich Western nations ordering hundreds of millions of doses in an “us first” strategy.

Vaccine nationalism: Rich nations spend BILLIONS to grab first anti-coronavirus doses while poor countries are left behind (again) — RT Op-ed

COVID-19 vaccine cold war! - The Peninsula Qatar

Three vaccines are in final-stage trials and a fourth is nearly there.Three vaccines are in final-stage trials and a fourth is nearly there.

The Health 202: These are the top coronavirus vaccines to watch - The Washington Post

It's dog eat dog in the world of COVID-19 vaccines.It's dog eat dog in the world of COVID-19 vaccines.

'Vaccine nationalism': Is it every country for itself? - Reuters

Johns Hopkins researchers warn COVID vaccine delivery, distribution problems are looming

Human challenge trials and equitable distribution of vaccines were extensively discussed in this symposiumHuman challenge trials and equitable distribution of vaccines were extensively discussed in this symposium

Human Challenge Trial For COVID-19 Unnecessary: Anthony Fauci At ICMR Event

India, Israel working on 4 rapid tests.India, Israel working on 4 rapid tests.

Trials for 30-second COVID-19 tests begin - The Hindu

covid shield covishield serum institute covishield india covishield vaccine news covishield vaccine in india covid shield india covishield oxford covishield oxford vaccine covid vaccine oxford covid vaccine trial covid vaccine italy covid vaccine usa covid vaccine updates covid vaccine price covid vaccine india status covid vaccine aiimsAbout 1,600 people aged above 18 will participate in the trials across 17 selected sites, including AIIMS Delhi, BJ Medical College, Pune, Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) Patna etc

COVID-19 Vaccine: Pune Firm Gets Nod For Human Trial of Covishield, 1,600 People to Participate

WHO urges countries to support 'COVAX' vaccine scheme - CGTN

CanSino Biologics Inc , one of many companies worldwide trying to develop a coronavirus vaccine, needs to conduct late-stage trials overseas if it is to stay in the race, experts say, but it has yet to announce another country willing to help. Mid-stage trials showed that its vaccine did not work as well in people with immunity to a particular strain of the common cold virusCanSino Biologics Inc , one of many companies worldwide trying to develop a coronavirus vaccine, needs to conduct late-stage trials overseas if it is to stay in the race, experts say, but it has yet

Big obstacle: Where can CanSino test vaccine abroad? | Deccan Herald

Central Drugs Standard Control Organisation, CDSCO, Serum Institute of India, Serum Institute, COVID-19 vaccine, coronavirus vaccine The Subject Expert Committee at Central Drugs Standard Control Organisation (CDSCO) has recommended to the top drug regulator to grant permission to Serum Institute of India (SII) to conduct phase two and three clinical trials in India on a potential COVID-19 vaccine.

Oxford COVID-19 vaccine: Panel recommends DCGI to grant Serum Institute approval for human trial | India News – India TV

The coronavirus stories Medscape''s editors around the globe think you need to know about today.The coronavirus stories Medscape''s editors around the globe think you need to know about today.

COVID-19 Update: PPI Risk, Aerosol Transmission

Tune in to the Coronavirus Essential podcast with Sakshi Batra for all the top updates on the ongoing pandemic.Tune in to the Coronavirus Essential podcast with Sakshi Batra for all the top updates on the ongoing pandemic.

Coronavirus Essential podcast | Health ministry aims to conduct 10 lakh tests per day; Oxford vaccine showing good progress, says AstraZeneca - Moneycontrol.com

Access Denied

Coronavirus vaccine news update: Biocon founder Kiran Mazumdar-Shaw said that the first doses of the vaccine should be administered to young people and health workersCoronavirus vaccine news update: Biocon founder Kiran Mazumdar-Shaw said that the first doses of the vaccine should be administered to young people and health workers

Coronavirus vaccine update: Eyes on India as candidates race towards finish line

While US infectious diseases expert Anthony Fauci said long-term effects of exposure to Covid are yet unknown, others said human challenge trials could quicken vaccine search.While US infectious diseases expert Anthony Fauci said long-term effects of exposure to Covid are yet unknown, others said human challenge trials could quicken vaccine search.

Human challenge trials for Covid vaccine unnecessary, unethical — Fauci at ICMR symposium

While US infectious diseases expert Anthony Fauci said long-term effects of exposure to Covid are yet unknown, others said human challenge trials could quicken vaccine search.While US infectious diseases expert Anthony Fauci said long-term effects of exposure to Covid are yet unknown, others said human challenge trials could quicken vaccine search.

Human challenge trials for Covid vaccine unnecessary, unethical — Fauci at ICMR symposium

The coronavirus pandemic has been good news for investors in pharma companies racing to develop a Covid-19 vaccine. Stock prices for many of the competing companies are trading around record highs. Some examples: Moderna’s (NASDAQ: MRNA) value has jumped 4x from about $8 billion at the beginning...The coronavirus pandemic has been good news for investors in pharma companies racing to develop a Covid-19 vaccine. Stock prices for many of the competing companies are trading around record highs. Some examples: Moderna’s (NASDAQ: MRNA) value has jumped 4x from about $8 billion at the beginning...

Are Covid Vaccine Stocks Worth Investing In?

WASHINGTON, July 31 — The Trump administration anticipates launching a far-reaching promotions campaign by November to encourage Americans to get vaccinated against the coronavirus, contingent on evidence that a successful vaccine will be available roughly by year end, a senior administration...WASHINGTON, July 31 — The Trump administration anticipates launching a far-reaching promotions campaign by November to encourage Americans to get vaccinated against the coronavirus, contingent on evidence that a successful vaccine will be available roughly by year end, a senior administration...

US government to launch 'overwhelming' Covid-19 vaccine campaign by November | World | Malay Mail

New Delhi [India], July 31 (ANI): The Subject Expert Committee at Central Drugs Standard Control Organisation (CDSCO) has recommended to the top drug regulator to grant permission to Serum Institute of India (SII) to conduct phase two and three clinical trials in India on a potential COVID-19 vaccine, a Health Ministry official said on Friday.New Delhi [India], July 31 (ANI): The Subject Expert Committee at Central Drugs Standard Control Organisation (CDSCO) has recommended to the top drug regulator to grant permission to Serum Institute of India (SII) to conduct phase two and three clinical trials in India on a potential COVID-19 vaccine, a Health Ministry official said on Friday.

Drug regulator gets committee approval for nod to clinical trials by Serum Institute for Oxford COVID-19 vaccine

New Delhi : In the development related to the COVID-19 vaccine across the world, only three vaccine candidates are in phase III clinical trials across the globe. These three coronavirus vaccine candidates are from the USA, UK (University of Oxford’s vaccine) and China, informed the official from the Union Health Ministry on Thursday. While there […]

COVID-19 vaccine development: Only 3 vaccine candidates in phase III across world - News Live TV

Even if some Americans opt out, the country will still reach herd immunity against COVID-19.Even if some Americans opt out, the country will still reach herd immunity against COVID-19.

People Are Suffering Too Much to Refuse a Vaccine - The Atlantic

AstraZeneca has reported that it has obtained 'good data so far' on its Covid-19 vaccine candidate, which is currently in large-scale clinical studies.AstraZeneca has reported that it has obtained 'good data so far' on its Covid-19 vaccine candidate, which is currently in large-scale clinical studies.

AstraZeneca reports good progress of Covid-19 vaccine in trials

Most viruses produce a long-lasting memory in a person’s immune system, but this is not always the case, says an observer.Most viruses produce a long-lasting memory in a person’s immune system, but this is not always the case, says an observer.

Commentary: Booster shots will likely be needed even if a COVID-19 vaccine is ready - CNA

Clinical trials in Canada of an early Chinese front runner in the race for a coronavirus vaccine are in limbo, with Chinese customs authorities holding up shipment of the injections for weeks.Health Canada gave approval for clinical trials for Ad5-nCoV, a potential vaccine developed jointly by Tianjin-basedClinical trials in Canada of an early Chinese front runner in the race for a coronavirus vaccine are in limbo, with Chinese customs authorities holding up shipment of the injections for weeks.Health Canada gave approval for clinical trials for Ad5-nCoV, a potential vaccine developed jointly by Tianjin-based

Coronavirus: Chinese customs stalls vaccine shipment for trials in Canada

Here are the COVID-19 vaccine prospects that have made it to phase three trials and beyond.Here are the COVID-19 vaccine prospects that have made it to phase three trials and beyond.

Dozens of COVID-19 vaccines are in development. Here are the ones to follow.

Over a dozen Indian companies are in partnership with other firms and institutes to bring a preventive vaccine into global markets by 2021.Over a dozen Indian companies are in partnership with other firms and institutes to bring a preventive vaccine into global markets by 2021.

Emerging landscape of COVID-19 vaccines in India as of 31 July: Bharat Biotech, Serum Institute, Zydus at the helm - India News , Firstpost

The concern is that vaccine supply and allocation in this coronavirus pandemic will echo the last - caused by the H1N1 flu virus in 2009/2010 - when rich nations bought up the available supply of vaccines, initially leaving poor countries with none.The concern is that vaccine supply and allocation in this coronavirus pandemic will echo the last - caused by the H1N1 flu virus in 2009/2010 - when rich nations bought up the available supply of vaccines, initially leaving poor countries with none.

‘Vaccine nationalism’: Is it every country for itself? | coronavirus outbreak News,The Indian Express

AstraZeneca has struck a number of deals around the world to supply the experimental COVID-19 vaccine, which has shown promise in early testing.AstraZeneca has struck a number of deals around the world to supply the experimental COVID-19 vaccine, which has shown promise in early testing.

AstraZeneca: Won’t profit from COVID-19 vaccine in pandemic | coronavirus outbreak News,The Indian Express

Several coronavirus vaccine trials have reached the final Phase 3 stage of testing ahead of potential approvals from regulators. Researchers are targeting efficacy of at least 60% for the drugs, according to Dr. Anthony Fauci, which is the standard for vaccines.Several coronavirus vaccine trials have reached the final Phase 3 stage of testing ahead of potential approvals from regulators. Researchers are targeting efficacy of at least 60% for the drugs, ac…

This might be the best coronavirus vaccine news you’ve ever heard – BGR

Companies could struggle to enrol enough trial participants, or gather enough data to convince regulatory agencies that the shots work. Companies could struggle to enrol enough trial participants, or gather enough data to convince regulatory agencies that the shots work.Companies could struggle to enrol enough trial participants, or gather enough data to convince regulatory agencies that the shots work.

China’s coronavirus vaccines are leaping ahead – but face challenges as virus wanes

In the development related to the COVID-19 vaccine across the world, only three vaccine candidates are in phase III clinical trials across the globe. These three coronavirus vaccine candidates are from the USA, UK (University of Oxford's vaccine) and China, informed the official from the Union Health Ministry on Thursday.In the development related to the COVID-19 vaccine across the world, only three vaccine candidates are in phase III clinical trials across the globe. These three coronavirus vaccine candidates are from the USA, UK (University of Oxford's vaccine) and China, informed the official from the Union Health Ministry on Thursday.

Only 3 COVID-19 Vaccine Candidate In Phase 3 Across The Globe: Centre

The Centre said it is currently deliberating on two key issues —logistics and to which section of the population the vaccine needs to be administered on priority.The Centre said it is currently deliberating on two key issues —logistics and to which section of the population the vaccine needs to be administered on priority.

Within govt, talks on who will get vaccine first | India News,The Indian Express

The development comes three days after the Subject Expert Committee (SEC) for Covid-related therapies on Tuesday recommended amendments to Serum’s earlier protocol to conduct the trials here.The development comes three days after the Subject Expert Committee (SEC) for Covid-related therapies on Tuesday recommended amendments to Serum’s earlier protocol to conduct the trials here.

Panel recommends nod to Serum for late-stage Oxford vaccine trials | India News,The Indian Express

A Covid-19 vaccine is coming soon, and when it does arrive, it will spark a huge, multi-quarter rebound in GE stock.A Covid-19 vaccine is coming soon, and when it does arrive, it will spark a huge, multi-quarter rebound in GE stock.

Here’s How GE Stock Could Almost Double in 18 Months | InvestorPlace